8.77
6.43%
0.53
Handel nachbörslich:
8.85
0.08
+0.91%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt AUPH?
Forum
Prognose
Aktiensplit
Aurinia Pharmaceuticals Inc Aktie (AUPH) Neueste Nachrichten
Layoff Tracker: J&J, Merck Trimming Workforces in China - BioSpace
Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis - sharewise
(AUPH) Technical Pivots with Risk Controls - Stock Traders Daily
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Position Reduced by GSA Capital Partners LLP - MarketBeat
Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024 - sharewise
ARMISTICE CAPITAL, LLC's Strategic Reduction in Aurinia Pharmace - GuruFocus.com
Aurinia to Participate in Jefferies London Healthcare Conference - sharewise
Aurinia Pharmaceuticals Engages at London Conference - TipRanks
Aurinia Pharmaceuticals director Karen Smith sells $44,181 in stock - Investing.com India
Aurinia Pharmaceuticals director sells shares valued at $38,415 - Investing.com India
Aurinia Pharmaceuticals director sells shares valued at $38,415 By Investing.com - Investing.com Canada
Aurinia Pharmaceuticals director Karen Smith sells $44,181 in stock By Investing.com - Investing.com UK
Aurinia Pharmaceuticals (NASDAQ:AUPH) Upgraded at StockNews.com - Defense World
Aurinia Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St
Aurinia stock jumps 14% on Q3 earnings, restructuring announcement - MSN
Aurinia offers slimmer profile after investor pressure - The Pharma Letter
Leerink Partnrs Issues Optimistic Estimate for AUPH Earnings - MarketBeat
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q3 2024 Earnings Call Transcript - Insider Monkey
Aurinia Pharmaceuticals: A Potential Buyout Looms On The Horizon (NASDAQ:AUPH) - Seeking Alpha
Aurinia slashes workforce by 45% to focus on lupus and autoimmune assets - Pharmaceutical Technology
Earnings call: Aurinia Pharmaceuticals announced a 24% increase in total net revenue - Investing.com
Aurinia Pharmaceuticals Inc (AUPH) Quarterly 10-Q Report - Quartz
Aurinia Pharmaceuticals Announces Restructuring - citybiz
Aurinia Pharmaceuticals (NASDAQ:AUPH) Stock Price Up 11%Should You Buy? - MarketBeat
Aurinia: Q3 Earnings Snapshot - The Washington Post
Aurinia stock jumps 14% on Q3 earnings, restructuring announcement (NASDAQ:AUPH) - Seeking Alpha
Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS® Growth and AUR200 Development - sharewise
Aurinia Pharmaceuticals (AUPH) Q3 Earnings and Revenues Beat Estimates - Yahoo Finance
Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors - citybiz
Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth - Business Wire
Long Term Trading Analysis for (AUPH) - Stock Traders Daily
Shareholders in Aurinia Pharmaceuticals (NASDAQ:AUPH) are in the red if they invested three years ago - Yahoo Finance
Aurinia Pharmaceuticals (AUPH) to Release Earnings on Thursday - MarketBeat
Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024 - The Bakersfield Californian
Axonis Therapeutics Announces $115 Million Series A Financing - Quantisnow
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) surges 5.9%; individual investors who own 51% shares profited along with institutions - Simply Wall St
Objective long/short (AUPH) Report - Stock Traders Daily
Oppenheimer Downgrades Aurinia Pharmaceuticals Inc (AUPH) to a Perform from an Outperform - Knox Daily
Adversity is less terrifying than hope: Aurinia Pharmaceuticals Inc (AUPH) - SETE News
AQR Capital Management LLC Takes Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - Defense World
AQR Capital Management LLC Buys Shares of 202,241 Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - MarketBeat
Aurinia Pharmaceuticals spotlights lupus nephritis drug - Investing.com India
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):